The adenovirus E1A protein contains three well conserved regions, designated conserved region (CR) 1, 2 and 3, which are important for the multiple activities ascribed to E1 A. The CR3 domain constitutes a prototypic transcription activator, consisting of a promoter targeting region and a transactivating region. Here we demonstrate the existence of a second transactivating region located within amino acids 28 to 90 (essentially the CR1 domain) of the E1A protein. A fusion protein, containing the Gal4 DNA binding domain linked to CR1, was as efficient as the classical CR3 transactivator in activating transcription from a reporter plasmid containing Gal4 binding sites. However, competition experiments suggest that Gal/CR1 and Gal/CR3 work through different cellular targets. The E1A-243R protein has previously been extensively characterized as a repressor of transcription. Here we show that a Gal4 fusion protein expressing the CR1 domain is indeed sufficient for repression of SV40 enhancer activity. Collectively, our results suggest that CR1 functions as an activator if tethered to a promoter and as a repressor in the absence of promoter association.
INTRODUCTION
The adenovirus El A gene encodes a family of proteins which include members that can both transactivate and transrepress viral and cellular transcription. Two structurally homologous proteins, of 243 and 289 amino acids (E1A-243R and E1A-289R), are the major products encoded by El A (1) . Three regions within E1A-289R, designated conserved region (CR) 1, 2 and 3, which are highly conserved between El A proteins from different adenovirus serotypes (2) , are also important for the multiple activities ascribed to El A (reviewed in 3). The classical El A transcription activation domain is contained within CR3 and unique to the E1A-289R protein. This domain has been suggested to participate in transcription activation by physically interacting with both basal and upstream binding transcription factors, as well as stimulating transcription by inducing phosphorylation of certain transcription factors (reviewed in 4).
Although CR3 is considered the main El A transactivation domain, recent reports have identified promoters which are specifically activated by the E1A-243R protein. Particularly the first exon of E1A-243R contains sequences which play an important role in transactivation of some viral and cellular promoters. E1A-243R transactivation of the adenovirus E2 promoter has been most extensively characterized. At this promoter, E1A-243R stimulates the activity of the transcription factor E2F by dissociating inactive heteromeric transcription factor complexes consisting of transcription factor E2F and the cellular plO5 retinoblastoma anti-oncogene (pl05-Rb) (5, 6, 7) . This dissociation requires El A sequences in CR1 and CR2. Still, this mechanism can not explain all of the transcription activating functions assigned to the first exon, since many E1A-243R inducible promoters lack E2F binding sites. For example, E1A-243R activation of the PCNA promoter is dependent on a cw-acting sequence spanning at least three overlapping transcription factor consensus binding sites (8) , whereas activation of the hsp70 gene requires the TATA-box element (9) .
In addition to activating a restricted set of promoters the E1A-243R protein has been shown to repress transcription of many RNA polymerase II genes (10, 11, 12, 13, 14 and references therein) and the adenovirus VA RNA genes, transcribed by RNA polymerase HI (15) . The CR1 domain is of critical importance for this ElA-mediated repression of transcription (13, 16, 17, 18, 19) .
Here we show that a 63 amino acid peptide, comprising CR1, contains a transactivator which is as potent as CR3 when analyzed in a Gal/El A fusion protein assay or when anchored to a promoter through protein/protein interaction with transcription factor ATF-2. In contrast to the CR3 domain, the Gal4/CR1 fusion protein has the capacity to repress the activity of the SV40 enhancer. Collectively, our data suggest that CR1, in the absence of promoter targeting, functions as a repressor of transcription. It is noteworthy that the CR1 domain has been shown to be essential for transformation (19, 20) . Thus, the dual gene regulatory activities of CR1 described here may be of importance for adenovirus induced transformation.
MATERIALS AND METHODS

Plasmid DNA
The Gal/El A fusions described in this investigation contain amino acids 1 to 147 or 1 to 94 of the yeast Gal4 transcription factor and are derivatives of the Gal4ElA (here designated Gal/C13SXoff) previously described (21) . The nomenclature used to name the plasmids are as follows; Met, R and C indicate that the junction between the Gal4 region and the adenovirus 2 El A sequence are at the El A initiation Methionine (Met), the Rsal site at nucleotide position 636 (R) or the Cla\ site at position 917 (C). El A sequences derived from the E1A-243R protein are designated 12S and E1A sequences derived from the El A-289R protein are designated 13S. Boff, Doff and Xoff indicate that a translational stop codon was introduced after the BspEl (position 825), Ddel (position 1241) and Xbal (position 1336) restriction sites, respectively.
Gal/C13SDoff encodes E1A residues 121 to 192 and was constructed by PCR amplification of primer extended mRNAs from cells transfected with the Ad2 El A mutant pKGO007Doff (22) . The Drain to Xbal fragment from the amplified DNA was inserted into the corresponding sites in pGal/C13SXoff. Gal/R13SDoff, containing amino acids 28 to 192 of E1A, was constructed by inserting the Rsal to DraUl fragment of pKGO007SVRI (23) into Gal/C13SDoff digested with Smal and Dram. Gal/R12SEP~ was constructed by PCR amplification and encodes amino acid 28 to 142 of the E1A-243R protein. Gal/RBoff encodes El A amino acids 28 to 90 and was created by blunt-end ligation of BspEl to Xbal in Gal/R13SDoff. Gal/R12SEP~ACR1 was constructed by replacing the EcdKl to BspEl fragment of Gal/R12SEP-with a Rsal to BspEl fragment of pKGO007ACRl,2a (22) using an £coRI linker. In Gal/R12SEP~ACR2a, the BspEl to Dralll fragment of Gal/R12SEP-was substituted by the BspEl to Dram fragment of pKGO007ACRl,2a (22) . Gal/MetBoff is a derivative of Gal/RBoff. It was constructed by PCR amplification and contains amino acids 1 to 90 of E1A. To construct R12S/E2 and C13S/E2 the DNA sequence corresponding to amino acids 28 to 144 of E1A-243R and 121 to 190 of E1A-289R, respectively, was amplified by PCR and introduced into BamHl and Kpnl digested pCMVE2 wt ori vector encoding the bovine papilloma virus E2 gene (24) . InfGal/RBoff, is identical to Gal/RBoff, except for an in frame deletion of amino acids 95 to 147 of the Gal4 domain and the presence of an Influenza epitope tag (25) at the amino terminus of Gal4. InfGal/RBoff (36) (37) (38) and InfGal/RBoff (66-68) are derivatives of InfGal/RBoff and were constructed using specific PCR primers to introduce substitutions of El A amino acids 36 to 38 (SHF to RLD) and amino acids 66 to 68 (FPE to SRK), respectively. pML005 is a derivative of pKGO007SVRI (23) containing nucleotides 1 to 1773 of the Ad2 genome. In pML005ACRl, wild type sequences were replaced by a Pstl to BspEl fragment from pKGO007ACRl (26) spanning a deletion of amino acids 38 to 65 (19) . pML005B"Xm and pML005ACRlB"Xm contain in frame deletions of amino acids 91 to 150, created by blunt end ligation of BspEl (position 825) to Xmal (position 1006). pML005pm563 was derived by PCR from the Ad5 virus mutant pm563 (27) .
The CAT reporter constructs have been described previously (21, 28).
Transfections and reporter gene analysis
Cells were maintained in Dulbecco's modification of Eagle's medium (DMEM) supplemented with 10% newborn calf serum. 1 h before transfection the medium was replaced with DMEM containing 10% fetal calf serum. Cells were transfected by the calcium phosphate coprecipitation technique (29) using a total of 10 ng DNA per 60 mm culture dish. The standard transfection cocktail contained 1 to 3 ng reporter plasmid, 0.5 to 5 fig El A activator plasmid and when so indicated, 5 /tg competitor DNA. After 10 h cells were treated with 15% glycerol in HBS buffer (160 mM NaCl, 25 mM HEPES pH 7.1 and 0.75 mM NH 2 PO 4 ). 48 h post-transfection, cells were harvested and lysed either by IsoB-Nonidet P40 treatment (lOmM Tris pH 7.9, 150 mM NaCl, 1.5 mM MgCl 2 and O.65% Nonidet P40) or through freeze-thawing. Chloramphenicol acetyl transferase assays were performed as previously described (30) . Quantitative results were obtained by phosphorimager scanning using the Image Quant program (Molecular Dynamics). Conditions for Nuclease SI analysis of rabbit /3-globin mRNA expression were as previously described (31) .
Protein expression analysis
Immunoprecipitations were performed as described previously (32) using the rabbit polyclonal anti-Gal antibody (a gift from M.Ptashne), or the mouse monoclonal antibodies Ml, M2 or M73 (33) . Immunoprecipitated E1A proteins in Fig. 3A were dephosphorylated with 3 U of bacterial alkaline phosphatase (SIGMA) in 0.1 M Tris, pH7,9. Western blots were done onto nitrocellulose membranes (BA 85, Schleicher and Schiiell). Hybridization to primary antibody Ml (33) and enhanced chemiluminescence were carried out using an ECL Western blotting system as described by the manufacturer (Amersham).
RESULTS
The E1A-289R protein contains two separate transcription activators Several reports have shown that the amino-terminal fragment of El A has transcription regulatory properties. To search for transcription activation domains in El A, located outside of CR3, the amino-terminal fragment of the El A-243R protein (residues 28 to 142), was fused to the yeast Gal4 (1 -147) DNA binding domain (Gal/R12SEP~; Fig. 1A ). The transcription activation capacity of this plasmid was compared to Gal/C13SXoff and Gal/C13SDoff containing the CR3 domain from E1A-289R (Fig.  1A) . Transactivation was measured following cotransfection of HeLa cells with a CAT reporter plasmid driven by a synthetic promoter containing five Gal4 binding sites upstream of the adenovirus E1B-TATA element (G5E1BCAT). As expected from previous results (21) , Gal/C13SXoff efficiently enhanced CAT expression, but also Gal/R12SEP~ resulted in a large increase in CAT activity (Fig. 1A) . Previous results have shown that CR3 constitutes a critical domain required for El A transactivation (reviewed in (34) which can activate transcription from the E1B TATA element. We were, however, unable to detect any transactivation of the G5E1BCAT by wild type E1A proteins (ElA wt and E1A-12S; Fig 1A) , nor transactivation of an E1BTATACAT reporter lacking Gal4 binding sites by the Gal/El A fusions (data not shown). Since the lack of activation may be due to the very low basal expression from a E1BTATA- only reporter, we instead compared the ability of Gal/R12SEPã nd Gal/C13SXoff to activate the adenovirus E4 promoter (E4CAT; Fig. IB ) and a derivative thereof containing Gal4 binding sites (G5E4CAT; Fig. IB ). The E4 promoter constructs contain adenovirus sequences from -240 to +32 and were, as expected, activated by Gal/CR3 irrespectively of the presence or absence of Gal4 binding sites. In contrast, transactivation by Gal/R12SEP~ was strictly dependent on Gal4 binding sites and thus essentially no transactivation of the wild type E4 promoter was observed (Fig. IB) . Together these results suggest that the amino-terminal fragment of the E1A-243R protein contains a potent transactivator which becomes active only when it is bound to the target promoter.
To prove that the novel amino-terminal transactivator was independent of the origin of the DNA binding domain, the Gal4 DNA binding domain was substituted with a fragment encoding the corresponding region from the bovine papillomavirus E2 trans-activator (35) , thus creating fusion proteins R12S/E2 and C13S/E2. As shown in Figure 1C , both E2 fusion proteins efficiently activated transcription from a CAT reporter containing one binding site for the E2 DNA binding domain (pE2RElCAT) (28) . Thus, both CR3 and the E1A-243R amino-terminal activator functioned with similar efficiency irrespective of whether they are presented head or tail of the DNA binding domain.
A potent transactivator is located in conserved region 1 of the adenovirus E1A protein
The amino-terminal exon of the El A proteins contains two wellconserved regions, CRl and CR2, which are of critical importance for direct and indirect interactions between El A and a number of cellular proteins; the best characterized being pl05-Rb, pl07, p300, cyclin A and cdk2 (reviewed in 36). To study the importance of these interactions in the novel exon 1 transactivator function a series of deletion mutants originating from Gal/R12SEP~ (Fig. 1A) were constructed. As shown in Fig. 2 , a 28 amino acid deletion removing most of CRl (residues 38-65; Gal/R12SEP~ACR1) completely eliminated the exon 1 transactivation potential. Mapping of the novel activator to the CRl domain was corroborated by the demonstration that a smaller fusion protein, Gal/RBoff, containing a 63 amino acid fragment spanning CRl (residues 28-90) was an even better transactivator than Gal/R12SEP~. A five amino acid deletion in CR2 also resulted in a more efficient transactivation compared to Gal/R12SEP-(Gal/R12SEP-ACR2a; Fig. 2 ). As expected, this deletion eliminated detectable binding of both plO5-Rb and plO7 in a coimmunoprecipitation assay (26) (Fig. 3) . Also, a three amino acids substitution mutant [InfGal/RBoff(36-38); Fig. 2] , where the positions of the nonconservative substitutions (SHF to RLD) were selected such that they should interfere with plO5-Rb and plO7 binding (37) , retained full transactivating capacity. Thus, pl05-Rb or pl07 association to E1A was not required for the novel CRl transactivator function, but rather had a negative effect. This conclusion was further confirmed by showing that Gal/RBoff retained full transactivation capacity in the pl05-Rb negative cell line OHS (38, 39) (data not shown). ElA binding to p300 has been shown to require non-contiguous ElA sequences located at the extreme amino-terminus and within CRI (37) (Fig. 3A) . A mutant with amino acid substitutions in residues 66 to 68 (FPE to SRK), which are important for p300 binding, demonstrated less than 2% of the transactivation capacity of the parental protein (compare InfGal/RBoff(66-68) and InfGal/RBoff; Fig. 2 ) However, inclusion of ElA amino acids 1 to 27, needed for p300 binding in the wild-type ElA proteins, resulted in a decreased transactivation ability (compare Gal/RBoff and Gal/MetBoff; Fig 2) . To exclude competition between the anti-Gal antibody and p300 in binding to the Gal/El A fusion protein, the Gal/12S, containing the complete E1A-243R amino acid sequence, was immunoprecipitated with the anti-ElA antibody M73. Unexpectedly, even after including El A residues 1 to 27 we were unable to detect coprecipitation of p300 (Fig.  3A) . These results suggested that the Gal4 DNA binding domain interferes with p300 binding to El A and are consistent with the hypothesis that the CR1 transactivator contained in Gal/RBoff does not correlate with El A binding to the p300 protein.
Furthermore, Fig. 3A , B and C demonstrate that almost all Gal/El A fusion proteins used in this investigation are made in roughly equal amounts. InfGal/RBoff(66-68) accumulates to approximately 25% of InfGal/RBoff fusion protein levels (Fig.  3B) . This difference in steady-state protein levels is, however, not in parity with the almost 60-fold difference in transactivation capacity between InfGal/RBoff and InfGal/RBoff(66-68). Moreover, when the amounts of transfected plnfGal/RBoff and pInfGal/RBoff(66-68) were adjusted to give comparable amounts of proteins, the difference in transactivation remained essentially unaltered (data not shown). Thus, we conclude that variations in protein expression does not account for the observed differences in transactivation potential.
Different cellular targets for CR1 and CR3 transactivation
The CR3 domain of E1A-289R binds to several cellular transcription factors (40, 41, 42, 43, 44) as well as the TATAbox binding (TBP) component of TFIID (45, 46) . The fact that the Gal/CR3 fusion proteins activate transcription from a reporter containing only a TATA box and an upstream binding site for the Gal4 protein implicates a mechanism where the CR3 domain facilitates the formation of a transcription competent initiation complex at a core promoter element. To determine whether the same cellular target was required for CR1 and CR3 induced transcription, Gal/RBoff or Gal/C13SXoff mediated activation of G1E1BCAT transcription was competed by cotransfection of plasmids encoding wild-type or mutant El A proteins. The native E1A proteins do not recognize the Gal4 binding site in the G1E1B promoter and can therefore not activate transcription from this reporter (Fig. 1A) . As shown in Fig. 4A , E1A-289R (pML005) efficiently inhibited transcription directed by either Gal/RBoff or Gal/C13SXoff, whereas an ElA-deletion mutant lacking CRl (pML005ACRl; Fig. 4A ) competed Gal/C13SXoff directed transcription but had no effect on Gal/RBoff transactivation. (Fig.  4A) . In a similar experiment, R12S/E2 efficiently competed Gal/RBoff mediated transcription, but not Gal/C13SXoff transcription (Fig. 4B ). Vice versa, C13S/E2 competed Gal/C13SXoff directed transcription, but not Gal/RBoff transcription (Fig.4B) . The SV40 enhancer/promoter driving the Gal/EIA constructs is a potential target for transrepression by the El A CRl domain. In agreement with this, the levels of Gal/EIA fusion proteins are reduced approximately 2-fold in the presence of the wt El A proteins (data not shown). This decrease is, however, not sufficient to account for the observed decrease in transactivation ( > 100-fold). Furthermore, as the R12S/E2 protein failed to inhibit transactivation by the Gal/C13Xoff we conclude that transrepression of the SV40 enhancer is unlikely to significantly contribute to the inhibition of transactivation. Collectively, these results suggest that the cellular targets for CRl and CR3 directed transcription are different. Additionally, the ability of wild-type El A proteins to compete CRl directed transactivation supports a model where the CRl transactivator interacts with a cellular target that transmit a positive signal to the basal transcription machinery, rather than by dissociating inactive transcription factor complexes.
Synergistic transactivation by CRl and CR3
The results presented above suggest that different cellular targets are involved in CRl and CR3 directed transactivation. However, in the end both regions have to transmit a signal to the basal transcriptional machinery. This suggests that CRl and CR3 might be able to activate transcription synergistically. To test this prediction, the transactivation property of a Gal/EIA fusion protein containing both transactivation domains (Gal/R13SDoff) was compared to derivatives containing either the CRl or CR3 domain; Gal/RBoff and Gal/C13SDoff (Fig. 4C) . The difference in activation potential between this experiment and the one shown in Figure 2 is caused by transfecting one fourth the amount of the individual Gal/EIA plasmids (compare 'Fold'-activation, Fig.  2 and 4C ). As shown in Figure 4C , Gal/RBoff and Gal/C13SDoff activated transcription 38-and 52-fold, respectively. When both transactivator regions were presented on the same molecule, a synergistic activation was observed (Gal/R13SDoff; 881-fold). Cotransfection of plasmids Gal/RBoff and Gal/C13SDoff, encoding the CRl and CR3 domains on separate proteins, also resulted in a dramatic increase in activation of CAT expression compared to Gal/RBoff or Gal/C13SDoff individually (445-fold; Fig. 4C ). Since the Gal/EIA fusion proteins bind DNA as a dimer these results suggested that a heterodimeric protein complex consisting of Gal/RBoff and Gal/C13SDoff also worked synergistically. The transactivation in this experiment was lower than when Gal/R13SDoff was used, probably because a mixture of homo and heterodimeric proteins are expected to be formed in Gal/RBoff and Gal/13SDoff cotransfected cells. Furthermore, homodimeric Gal/R13SDoff proteins will present four activating regions compared to two regions in the heterodimer consisting of Gal/RBoff and Gal/C13SDoff.
The observed increase in transactivation was not due to overexpression of the Gal/EIA proteins, since Western blot analysis did not reveal any significant increase of protein levels in protein extracts from cells transfected with plasmids expressing both CRl and CR3 (Fig. 3B and data not shown) .
Transactivation by CRl in the absence of artificial promoter localization
Although the wild-type E1A-289R protein does not bind DNA in a sequence specific manner (47, 48) , it is believed to become anchored to certain target promoters by interacting with some members of the ATF family of transcription factors, ATF-2 (42) or ATFal (41) . It is thought that ATF-2 and ATFal bind to their recognition sequences and recruit El A to the promoter through a CR3 mediated protein-protein interaction. CR3 can be divided into two subdomains; the ATF-2 promoter targeting sequence located at the carboxy-terminal end of CR3 and the activation domain located at the amino-terminal end of CR3 (21, 42) .
It has been demonstrated that El A mediates transactivation of promoters containing Gal4 binding sites by associating to Gal4/ATF-2 (42). To determine whether CRl could activate transcription through the ATF-2 pathway, the capacity of El A mutant proteins to activate a Gal4/ATF2 fusion protein was tested. In agreement with previous reports, cotransfection of pML005 and Gal4/ATF2 increased the activity of G5E1BCAT (32, 42) ; Fig. 5 ). A deletion of residues 38 to 65 (pML005ACRl; Fig. 5 ) had no significant effect on the transactivation potential of the El A proteins, suggesting that the structural location of CRl in the wild-type protein does not allow for it to transactivate through the ATF-2 pathway. In contrast, deletion of the CR3 specific activator domain (amino acids 91 to 150), without affecting the ATF-2 promoter targeting sequence (pML005B~Xm) resulted in a strictly CRl dependent transactivation (compare pML005B"Xm and pML005DCRlB"Xm; Fig. 5 ). Collectively these results suggest that CRl can activate transcription in the absence of an artificial DNA binding domain if provided with a natural promoter targeting signal at an appropriate location relative to CRl.
CRl dependent repression of SV40 enhancer activity
The transactivating capacity of CRl only seems to become evident under conditions where CRl is recruited to a promoter either through a DNA binding domain or through a protein-protein interaction. Strong activators, when expressed in excess or without a DNA binding domain, can often inhibit gene expression by squelching. To test whether the potent CRl activator domain also have a capacity to inhibit transcription we investigated the ability of InfGal/RBoff, InfGal/RBoff (36) (37) (38) and InfGal/RBoff(66-68) to repress transcription of a 0-globin reporter gene driven by the SV40 enhancer. As shown in Fig  6 , InfGal/RBoff efficiently repressed /3-globin expression. Furthermore, the subdomain of InfGal/RBoff necessary for transcription activation in a Gal/EIA fusion protein assay (Fig.  2) was also required for the SV40 enhancer repression activity (InfGal/RBoff (66-68); Fig. 6 ). These results are compatible with a mechanism where E1A-243R represses transcription by squelching a transcription factor required for SV40 enhancer activity.
This result is at first sight incompatible with the mechanism suggested for El A-243R repression of insulin enhancer activity (49) . In this context El A repression of transcription has been shown to correlate with the capacity of El A to stably associate with the cellular p300 protein (50) . However, in our experimental system, mutant pML005pm563, with a single amino acid change at position 2 which is of critical importance for p300 binding (51) (Fig. 3A) , was as effective as the wild-type E1A-243R protein (pML005) in repressing the SV40 enhancer (Fig. 6) . Together, these results suggest that El A repression of the SV40 enhancer and the insulin enhancer differs in the requirement for p300 binding.
DISCUSSION
We have previously shown that adenovirus mutants with deletions of amino acids 27 to 98 in the El A protein demonstrate impaired virus growth, inefficient late gene expression and failure to block host cell gene expression (52) . We now show that a corresponding segment of E1A-243R, between amino acids 28 to 90, including the CRl domain, constitutes a potent transcription activator. In fact, the CRl activator is as efficient as CR3 in stimulating transcription, when fused to the Gal4 DNA binding domain (Fig.  4C) . The capacity of CRl to activate transcription was initially observed in experiments where the CRl domain was linked to a heterologous DNA binding domain from the yeast Gal4 transactivator protein or the bovine papillomavirus E2 transactivator protein. Importantly, the CRl domain was also shown to activate transcription when it was tethered to a promoter through the ATF-2 promoter targeting signal of CR3 (42); (Fig.  5) . This suggested that the CRl domain was capable of activating transcription if it could become localized to a promoter through protein-protein interaction. However, ATF-2 is probably not the natural target for CRl activation since (i), CRl is dispensable for E1A transactivation through Gal/ATF-2 (Fig. 5) , and (ii), CRl cannot rescue transactivation through ATF-2 in an El A mutant where the activating, amino-terminal domain of CR3 has been inactivated by a two amino acids change (42) . Finally, since the amino-terminus of the E1A-243R protein has been shown to activate transcription of different promoters, such as the PCNA and the hsp70 promoters (8, 9) additional promoter targeting functions might exist in the El A proteins.
Transcription factor TFIID plays a central role in transcription initiation by RNA polymerase II. TFIID binds to the TATA element and recruits other basal transcription factors and the RNA polymerase to the core promoter (reviewed in 53). TFIID is a multiprotein complex consisting of the TATA binding protein (TBP) and several tightly TBP associated factors (TAFs) (54, 55) . Since the CR3 domain has been shown to make specific contacts with TBP (45, 46) an interaction between E1A-289R and TFIID may be of critical importance for stimulation of core promoter activity (56) . Both the Gal/RBoff and the Gal/C13SDoff fusion proteins activate transcription from a minimal promoter containing a TATA element and one Gal4 binding site. This indicates that both the CR1 and CR3 activators, directly or indirectly, communicate with the basal transcription machinery. However, two experiments suggest that CR1 and CR3 target different components of the transcription machinery. First, a heterodimer consisting of Gal/CRl and Gal/CR3 appears to function better than the corresponding Gal/CRl or Gal/CR3 homodimeric proteins (Fig. 4C) . If CR1 and CR3 were targeting the same factor one would have expected that the heterodimer would have the same activation capacity as the corresponding homodimers. Secondly, transactivation by the Gal/El A fusion proteins were only efficiently competed by E1A proteins encoding the homologous activating domains (Fig. 4A and B) . Thus, the CR3 domain could not repress CR1 directed transactivation. These results are consistent with the hypothesis that CR1 and CR3, either directly or through different adapters, contact different components of the basal transcription machinery. None of the many cellular proteins which have been shown to associate with the first exon of the El A proteins (reviewed in 36) appears to correlate with the CR1 transactivation function (Fig. 2 and  3 ). Our data suggest that CR1 -directed transactivation is mediated through an unidentified factor, which binds to the carboxyterminal half of CR1, overlapping the region contributing to p300 binding. This factor probably contacts the basal transcription machinery since Gal/CRl, in the absence of promoter binding, functions as a transcription repressor (Fig. 6 ).
Although the E1A-243R protein has a capacity to activate transcription of certain promoters it has also been described as a potent repressor of transcription (10, 12, 15, 17, 49, 57, 58, 59, 60, 61, 62, 63) . As we show here, the CR1 domain alone can inhibit SV40 enhancer dependent transcription (Fig. 6) . Furthermore, we show that the subregion of CR1 that is required for activation as a Gal/El A fusion protein, was also required for SV40 enhancer repression. Thus, Gal/RBoff may be repressing transcription by titrating out a limiting factor(s) required for the activity of the SV40 enhancer.
El A repression of transcription has often been suggested to correlate with El A binding of the cellular p300 protein. This conclusion usually rests on the observation that mutants unable to bind p300 are also deficient in transrepression (50, 61) . We show here that Gal/RBoff, encoding residues 28 to 90, efficiently repressed the activity of the SV40 enhancer (Fig. 6 ) despite the fact that no p300 binding to Gal/RBoff could be detected (Fig.  3A) . Furthermore, mutant pML005pm563, which has a single amino acid change at position 2 which eliminates p300 binding (51); Fig. 3 ) was as effective as wild-type El A in repressing SV40 enhancer driven transcription (Fig. 6) . Collectively, our results suggest that the SV40 enhancer can be repressed by a p300 independent mechanism. However, the wild-type E1A-243R protein was still a slightly better repressor than Gal/RBoff. This indicates that the E1A-243R protein might have the capacity to inhibit transcription through additional pathways. This hypothesis is in agreement with several other studies. For example, E1A repression of MyoD transactivation and VA RNA transcription has been shown to require El A sequences encompassing both CR1 and CR2 (15, 61) . Furthermore, CR2 and sequences in the carboxy-terminal exon have been shown to contribute to transrepression of certain genes and transcription factors (14, 22, 61, 64) . Most likely, future experiments will show that E1A-mediated transcription repression is complex, and regulated by multiple mechanisms. However, our experiments imply that CR1 dependent transcriptional squelching may be a very important mechanism for E1A repression of transcription.
